scispace - formally typeset
K

Kiran Bendale

Researcher at Cancer Research Institute

Publications -  10
Citations -  52

Kiran Bendale is an academic researcher from Cancer Research Institute. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 3, co-authored 6 publications receiving 28 citations.

Papers
More filters
Journal ArticleDOI

Accentuated osseointegration in osteogenic nanofibrous coated titanium implants

TL;DR: The findings of the present study confirm that osteogenic nanofibrous coating significantly increases the magnitude of osteogenesis in the peri-implant zone and favours the dynamics of osseointegration.
Journal ArticleDOI

Osteogenic Nanofibrous Coated Titanium Implant Results in Enhanced Osseointegration: In Vivo Preliminary Study in a Rabbit Model.

TL;DR: A titanium implant surface when coated with biodegradable, highly porous, osteogenic nanofibrous coating has shown enhanced intrinsic osteoinductive and osteoconductive properties which results in enhanced osseointegration of the implant.
Journal ArticleDOI

Albumin Based Iohexol Nanoparticles for Computed Tomography: An In Vivo Study.

TL;DR: This study interprets that Polyethylene glyocol Iohexol albumin nanoparticles have prolonged residence time producing much greater conspicuity of anatomic features and warrants further detail study of the formulation in disease models.
Journal ArticleDOI

Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells

TL;DR: In this paper , a non-invasive test for detection of prostate cancer based on functional enrichment of prostate adenocarcinoma associated circulating tumor cells (PrAD-CTCs) from blood samples followed by their identification by immunostaining for pancytokeratins (PanCK), prostate specific membrane antigen (PSMA), alpha methyl-acyl coenzyme-A racemase (AMACR), epithelial cell adhesion molecule (EpCAM), and common leucocyte antigen (CD45).
Journal ArticleDOI

Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers

TL;DR: The analytical and clinical validation of a Circulating Tumor Cell (CTC) assay to accurately assess the presence of PD-L1 22C3 and PD- L1 28.8, ER, PR and HER2, from patients with solid tumors to guide the choice of suitable targeted therapies are described.